Condition
Obesity
Overweight
Locations
United States
Start date
15/07/2026
Identifiers
Trial ID NN9559-8621,
NCT number NCT07710768,
Eudract number Not Available
NCT number NCT07710768,
Eudract number Not Available
Summary
The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.
Trial Overview:
Treatment
DRUG: UBT251
DRUG: Cocktail (Warfarin/Caffeine/Midazolam)
Study type
INTERVENTIONAL
Trial duration
Jul 15 2026 - Apr 07 2027
Participants
44
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 65 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.